Published in Ann Intern Med on June 21, 2005
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis | NCT01199887
Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis (EXAFIP) | NCT02460588
PROOF-Registry New and Extended Belgium -Luxembourg (PROOF-NEXT) | NCT03732859
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 3.42
WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest (2009) 3.33
Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol (2010) 2.96
Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One (2008) 2.94
Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 2.74
Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Idiopathic pulmonary fibrosis. Orphanet J Rare Dis (2008) 2.34
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Pulmonary fibrosis: patterns and perpetrators. J Clin Invest (2012) 2.05
Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med (2007) 2.00
Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91
Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med (2013) 1.89
Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One (2007) 1.88
A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One (2011) 1.87
Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest (2008) 1.65
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J (2015) 1.60
Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One (2009) 1.56
Rheumatoid lung disease. Proc Am Thorac Soc (2007) 1.55
Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med (2008) 1.53
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med (2015) 1.52
Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax (2005) 1.50
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Toll-like receptors, wound healing, and carcinogenesis. J Mol Med (Berl) (2008) 1.27
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J (2010) 1.26
From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med (2009) 1.24
TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med (2010) 1.21
Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol (2013) 1.17
Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology (2009) 1.16
Lung tissue mechanics as an emergent phenomenon. J Appl Physiol (1985) (2011) 1.15
Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS One (2013) 1.14
Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair (2008) 1.13
Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung (2010) 1.11
Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. Curr Rheumatol Rev (2010) 1.07
Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum (2012) 1.06
Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax (2006) 1.04
The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 1.04
New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs (2011) 1.03
Toll-like receptors, Notch ligands, and cytokines drive the chronicity of lung inflammation. Proc Am Thorac Soc (2007) 1.03
Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 1.01
Towards systems biology of human pulmonary fibrosis. Proc Am Thorac Soc (2007) 1.00
Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest (2014) 0.99
Molecular magnetic resonance imaging of pulmonary fibrosis in mice. Am J Respir Cell Mol Biol (2013) 0.99
Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med (2010) 0.99
Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts. J Biol Chem (2014) 0.97
Workshop on idiopathic pulmonary fibrosis in older adults. Chest (2010) 0.96
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology (2014) 0.96
Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation. Ann Am Thorac Soc (2015) 0.95
Application of carbon monoxide diffusing capacity in the mouse lung. J Appl Physiol (1985) (2011) 0.95
Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol (2014) 0.94
Clinical review: idiopathic pulmonary fibrosis acute exacerbations--unravelling Ariadne's thread. Crit Care (2010) 0.93
Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol (2011) 0.92
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med (2008) 0.91
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res (2010) 0.89
Idiopathic pulmonary fibrosis: CT and risk of death. Radiology (2014) 0.87
Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One (2015) 0.85
Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer. Pulm Med (2011) 0.85
Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS One (2014) 0.85
Personalized medicine: applying 'omics' to lung fibrosis. Biomark Med (2012) 0.84
A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med (2015) 0.83
Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2011) 0.83
Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res (2013) 0.83
IPF clinical trial design and endpoints. Curr Opin Pulm Med (2014) 0.83
Protein Arginine Methyltransferases (PRMTs): promising targets for the treatment of pulmonary disorders. Int J Mol Sci (2012) 0.82
High-resolution CT of complications of idiopathic fibrotic lung disease. Br J Radiol (2011) 0.81
TLR9-induced interferon β is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis. Fibrogenesis Tissue Repair (2011) 0.81
A network model of correlated growth of tissue stiffening in pulmonary fibrosis. New J Phys (2014) 0.81
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
What Is the Optimal Transplant for Older Patients With Idiopathic Pulmonary Fibrosis? Ann Thorac Surg (2015) 0.81
Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis (2015) 0.81
Second harmonic generation microscopy analysis of extracellular matrix changes in human idiopathic pulmonary fibrosis. J Biomed Opt (2014) 0.80
A sigmoidal fit for pressure-volume curves of idiopathic pulmonary fibrosis patients on mechanical ventilation: clinical implications. Clinics (Sao Paulo) (2011) 0.79
Approach to acute exacerbation of idiopathic pulmonary fibrosis. Ann Thorac Med (2013) 0.79
New perspectives on management of idiopathic pulmonary fibrosis. Ther Adv Chronic Dis (2016) 0.79
Quantitative assessment of lung ventilation and microstructure in an animal model of idiopathic pulmonary fibrosis using hyperpolarized gas MRI. Acad Radiol (2010) 0.79
Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med (2015) 0.79
Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) (2012) 0.79
Functional status after lung transplantation in older adults in the post-allocation score era. Am J Transplant (2012) 0.78
Clinical trials and tribulations--lessons from pulmonary fibrosis. QJM (2012) 0.78
Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis. Mucosal Immunol (2016) 0.78
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS One (2013) 0.77
Acute exacerbations in idiopathic pulmonary fibrosis. Ann Intern Med (2006) 0.77
Idiopathic pulmonary fibrosis: the need for early diagnosis. Multidiscip Respir Med (2013) 0.77
Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 0.77
Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology (2016) 0.77
Phenotyping mouse pulmonary function in vivo with the lung diffusing capacity. J Vis Exp (2015) 0.77
Aberrant innate immune sensing leads to the rapid progression of idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair (2012) 0.77
Idiopathic pulmonary fibrosis and coronary artery disease. Multidiscip Respir Med (2014) 0.77
Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis (2016) 0.76
Interstitial lung diseases: respiratory review of 2013. Tuberc Respir Dis (Seoul) (2013) 0.75
Fibrogenesis: Mechanisms, Dynamics and Clinical Implications. Iran J Pathol (2015) 0.75
Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis (2016) 0.75
Measurement of the pressure-volume curve in mouse lungs. J Vis Exp (2015) 0.75
Idiopathic pulmonary fibrosis in Saudi Arabia: Demographic, clinical, and survival data from two tertiary care hospitals. Ann Thorac Med (2014) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 9.40
Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med (2005) 8.49
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A (2007) 5.95
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 5.86
Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 5.82
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med (2010) 4.85
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron (2005) 4.78
Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med (2002) 4.66
Toll-like receptors in the pathogenesis of human disease. Nat Immunol (2004) 4.40
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Resolution of lung inflammation by CD44. Science (2002) 4.09
Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med (2002) 4.00
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Signaling properties of hyaluronan receptors. J Biol Chem (2001) 3.95
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A (2011) 3.82
Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol (2007) 3.62
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
In utero supplementation with methyl donors enhances allergic airway disease in mice. J Clin Invest (2008) 3.35
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res (2011) 3.25
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Protection from experimental asthma by an endogenous bronchodilator. Science (2005) 3.17
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Type 2 alveolar cells are stem cells in adult lung. J Clin Invest (2013) 2.93
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92
Pulmonary fibrosis associated with aluminum trihydrate (Corian) dust. N Engl J Med (2014) 2.88
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med (2004) 2.84
Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 2.74
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med (2007) 2.69
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65